CD22-CART

CD22-CART is an autologous Chimeric Antigen Receptor (CAR) T-cell therapy designed to treat B-cell malignancies. This innovative cell therapy involves collecting a patient's own T cells, genetically modifying them in vitro to express a CAR that specifically recognizes the CD22 protein, and then reinfusing these engineered T cells back into the patient. The CD22 protein is a B-lymphocyte antigen found on the surface of most B cells, including cancerous B cells, and is often retained even when other targets like CD19 are lost, making it a crucial target for patients who have relapsed after CD19-targeted CAR T-cell therapies. The activated CD22-CART cells then specifically target and eliminate CD22-expressing cancer cells. Development has largely been driven by academic institutions such as the National Cancer Institute, Stanford University, Children's Hospital of Philadelphia, and the Hospital of the University of Pennsylvania, with companies like Gracell Biotechnologies Ltd. also developing CD22-targeting CAR-T products. It is currently in clinical trials for various B-cell leukemias and lymphomas.

Other names

CD22 CAR T-cellsCD-22 CAR T-cellsCD 22 CAR T-cellsCD22-targeted CAR T-cellsCD-22-targeted CAR T-cellsCD 22-targeted CAR T-cells